Phase 1 Liver Cancer Trial, Recruiting NCT06687941 Sponsor: Aptamer Sciences, Inc. Condition: Liver Cancer
Back to Liver Cancer

Phase 1 Liver Cancer Trial, Recruiting

NCT06687941
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male or female and are 19 years old or older
  • You have been diagnosed with an advanced or returning solid tumor cancer, confirmed by laboratory testing of tissue or cell samples
  • Your tumor tests positive for a protein called GPC3, confirmed by a special lab test (called IHC)
  • You have at least one tumor spot that can be measured or tracked using medical scans
  • You are generally well enough to carry out light activity and care for yourself (confirmed with a standard doctor's assessment called ECOG 0 or 1)
  • Your doctor expects you to live for at least 12 weeks
  • Your blood counts, liver, kidneys, and heart are functioning at an acceptable level
  • If you have liver cancer (HCC), your liver disease is at a mild stage known as Child-Pugh Class A

Who may not be able to join:

  • You have a history of reduced blood flow to the heart (such as angina or a heart attack)
  • You have received any cancer treatment in the last 4 weeks
  • You have other serious health conditions that are not well controlled, such as high blood pressure or heart failure
  • You are pregnant, possibly pregnant, or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Lee, Aptamer Sciences, Inc.

Phone: +82-70-5067-4275

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Aptamer Sciences, Inc.
Registry
ClinicalTrials.gov
Start date
11 March 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Dose Limiting Toxicity (DLT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov